Insulet Corporation (PODD)

Market Cap	19.84B
Revenue (ttm)	2.07B
Net Income (ttm)	418.30M
Shares Out	70.14M
EPS (ttm)	5.78
PE Ratio	48.93
Forward PE	66.54
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,374,139
Open	276.04
Previous Close	288.29
Day's Range	274.87 - 286.66
52-Week Range	160.19 - 289.46
Beta	1.23
Analysts	Buy
Price Target	291.81 (+3.19%)
Earnings Date	Feb 20, 2025

About PODD

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company’s Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: May 15, 2007
• Employees: 3,000
• Stock Exchange: NASDAQ
• Ticker Symbol: PODD
• Website: https://www.insulet.com

Financial Performance

In 2024, Insulet's revenue was $2.07 billion, an increase of 22.07% compared to the previous year's $1.70 billion. Earnings were $418.30 million, an increase of 102.76%.

Analyst Forecast

According to 16 analysts, the average rating for PODD stock is "Buy." The 12-month stock price forecast is $291.81, which is an increase of 3.19% from the latest price.

Price Target

$291.81

(3.19% upside)

Analyst Consensus: Buy